Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and Psychological Outcomes After Monoclonal Gammopathy Screening: A Population-Based Screening Study and Subsequent Randomized Trial of Follow-Up.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Prediagnostic opioid use and survival in multiple myeloma: a nationwide register-based study.

Scientific reports·2026
Same author

Redefining light-chain smoldering multiple myeloma: prevalence and progression risk.

Leukemia·2026
Same author

Light Chain Monoclonal Gammopathy of Undetermined Significance: Diagnosis, Biology, and Clinical Management.

European journal of haematology·2026
Same author

Effects of chronic lymphocytic leukaemia (CLL)-directed therapy on diffuse large B-cell lymphoma (DLBCL) type Richter transformation compared to de novo DLBCL in a nationwide cohort.

British journal of haematology·2026
Same author

Exploring the Functional Impact of Individual <i>DDX41</i> Variants With a Fast and Robust Cell-Based Method.

Human mutation·2026

Related Experiment Video

Updated: Apr 24, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.2K

Identifying High-Risk Smoldering Multiple Myeloma for Early Intervention.

Cecilie V Maeng1,2,3, Sæmundur Rögnvaldsson4,5, Christian Brieghel1,3

  • 1Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

JAMA Oncology
|April 23, 2026
PubMed
Summary

The 2/20/20 model more accurately identifies high-risk smoldering multiple myeloma (SMM) patients for early treatment compared to AQUILA criteria. AQUILA criteria over-identifies patients, including those with lower progression risk.

More Related Videos

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.2K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.1K

Related Experiment Videos

Last Updated: Apr 24, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.2K
Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.2K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.1K

Area of Science:

  • Hematology
  • Oncology
  • Clinical Research

Background:

  • Smoldering multiple myeloma (SMM) is a precursor to active multiple myeloma, and early treatment may benefit high-risk patients.
  • Inconsistent definitions for high-risk SMM can lead to the inclusion of different disease subsets, complicating treatment decisions.

Purpose of the Study:

  • To compare the AQUILA trial inclusion criteria and the 2/20/20 risk stratification model for identifying high-risk SMM.
  • To assess the progression risk associated with each definition in distinct SMM cohorts.

Main Methods:

  • A cohort study utilizing data from the population-based Iceland Screens, Treats, and Prevents Multiple Myeloma (iStopMM) study and the Danish Lymphoid Cancer Resource (DALY-CARE) clinical database.
  • Retrospective analysis of progression risk based on initiation of treatment for individuals meeting high-risk criteria under both the AQUILA and 2/20/20 models.

Main Results:

  • The AQUILA criteria identified a higher proportion of high-risk SMM (34% in iStopMM, 55% in DALY-CARE) compared to the 2/20/20 model (8% in iStopMM, 19% in DALY-CARE).
  • Individuals classified as high-risk by the AQUILA criteria in the clinical cohort showed a 2-year progression risk of 27.0% (14.5% annual rate).
  • In contrast, those defined as high-risk by the 2/20/20 model exhibited a higher 2-year progression risk of 44.1% (27.3% annual rate).

Conclusions:

  • The 2/20/20 model more accurately identifies a high-risk SMM subgroup with a substantially higher progression risk compared to the AQUILA criteria.
  • These findings suggest that the 2/20/20 model is more suitable for selecting patients with SMM who are most likely to benefit from early therapeutic intervention.